Our vision is to democratize cell-based therapies for all patients.
Cell BioEngines, Inc., founded in Dec 2022, is a clinical-stage biotech company focused on developing allogeneic 'off-the-shelf' stem cell and its derived therapies as ‘drugs’ for treating human diseases.
We’re building a 'super-donor' stem-cell platform that can precisely generate any human cell type on demand and at scale to enable breakthrough therapies.
Cell BioEngines uniquely holds a portfolio of scalable manufacturing patents enabling the production of HLA-compatible cell therapies derived from cord blood stem cells, delivering both high scalability and reduced immune rejection risk.
OUR UNIQUE STRATEGY
We Develop Cell-based Products Both Within Our Company and Through Our Partner Company
Our Business Model is Focused on Expanding Our Portfolio of Product Opportunities
Allows Diversified Development of Multiple Programs Spanning Several Large Therapeutic Markets
OUR APPROACH
Cell Technology
Proprietary Stem Cell Platform Uniting Proven HLA Biology with Next-Gen Manufacturing
Product Pipeline
Cell-based Therapeutic Product Candidates to Transform Medicine and Healthcare
Time and space are not conditions of existence, time and space is a model for thinking
Albert Einstein
Our Goals
More than 1 disease at a time
More than 1 disease at a time
More than 1 disease at a time
We are therapeutic area agnostic which allows us maximum flexibility to focus on advancing cutting-edge stem cell-derived therapeutics approaches in oncology and regenerative medicine.
Decrease time to development
More than 1 disease at a time
More than 1 disease at a time
Allows us to pursue a broad range of products and product candidates with high clinical and commercial potential. This broad and deep diversification lowers the time to development and overall risk profile of the company.
Lower translational costs
More than 1 disease at a time
Lower translational costs
Low cost manufacturing enables us to act quickly to seize time-sensitive opportunities and provides us with a wider range of options from which to select the most ideal financial structure for each product.